Use and attention for sulfamides
1. Use of sulfamide (SD) 1. Oral use for treatment of general infections, adult first dose 2g per day, 2 g per day. Epidemic meningitis is prevented, with adults taking it 1 – 2g per day, 2 times; children taking it 0.25 – 0.5g per day, 2 times. 2. An intravenous injection or an intravenous drip for serious infections, such as tremor. Adult doses were generally 4g per day, with 2-4 slow intravenous injections or intravenous drips. The child dose is calculated on the basis of body weight and is normally 0.1 – 0.15 g/kg per day, with 2 – 4 points. (ii) Sulphuramine (SMZ) is frequently used in conjunction with Methoxymetrazine (TMP) (composite sulfadonate). Oral, 2 films per adult (each SMZ 0.4g, TMP0.08g) 2 times a day. The number of children is to be measured on the basis of weight, generally half a piece per child aged 2-5 years and one piece per child aged 6-12 years, two times a day. The dose may need to be increased when used for the treatment of Kapsilosis. (iii) Sulfadoctamine oral treatment of 0.5 – 1 g per adult per week. The first dose is doubled once a week for children 15 – 30 mg/kg.
1. Damage to the urology system In order to prevent this adverse reaction, an equal amount of sodium carbonate alkaline urine can be taken at the same time, and sufficient drinking water can be secured to provide no less than 1,500 ml of urine per day. During the use of the medicine, attention is paid to the observation of urine, and in case of abnormalities such as urination difficulties, timely medical attention is required. 2. Allergies can be manifested in rashes, rashes, skin skins, etc., and seepage multi-shaped red spots, allergies, etc. can occur in serious cases. Patients should be asked about their allergies prior to their use, and sulfamide-type substances are banned. If there are signs of skin aching, red spots, etc., during the course of the drug, it should be stopped immediately. 3. Blood system reactions may result in reduced particle cells, reduced slabs, regenerative obstructive anaemia, etc. Blood routines are periodically checked for long-term or large-dose use and, if abnormal blood indicators are detected, treatment programmes should be adjusted in a timely manner. 1. The combination of alkali drugs with alkali drugs such as sodium bicarbonate increases the solubility of sulfamine-type drugs in urine, but may also affect the absorption of other drugs in the gastrointestinal tract, such as those containing iron, calcium and magnesium ion, may form insoluble compounds and reduce therapeutic effects, which should be avoided and taken at the same time, if shared, at a time. 2. When used with other antibacterials and penicillin-like antibacterials, they may interfere with the fungicide of penicillin and are generally inappropriate. Combining with methylenedioxypyridium enhances antibacterial effects, but at the same time adverse effects may increase, requiring careful use and observation. 1. Sulfamide-type drugs for pregnant and lactating women may enter the foetus through a placental barrier, in combination with plasma protein for the foetus, and may lead to chlamydia for the newborn. At the same time, breast milk is available, with adverse effects on infants. Thus, pregnant and lactating women are prohibited from using or are cautiously using sulfamide-type drugs, which, if necessary, must be weighed against the advantages and disadvantages of a doctor. 2. Children are more vulnerable to adverse effects from the use of sulfamine-type substances, in particular damage to the urology system, as their liver and kidney functions are not fully developed. Drugs are to be used at doses that are strictly based on body weight and that closely observe adverse effects and ensure adequate drinking water. 3. Older persons: Renal function of older persons may decline, sulfado-type drugs are susceptible to urology problems, such as crystal urea, and are more susceptible to adverse blood system reactions, dosage adjustments when using drugs and enhanced monitoring of adverse effects. (iv) Use of 1. sulfamide-type drugs should be used on a medical basis, on time and on a volume basis, without any increase or reduction in doses or detoxification. 2. When preserving drugs, care shall be taken to keep them under the conditions required by the instructions in order to avoid deterioration. Do not use drugs if they are out of date or if they appear to be unusual, such as colour variations and different tastes. At the same time, during the treatment of sulfamide-type drugs, treatment should be provided in a timely manner in the event of abnormal symptoms such as fever, inactivity, respiratory difficulties and serious rashes.
